Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(5), 1235-1249 | ISSN:2251-6727

Pharmacological Induction and Modulation of Catalepsy: A Comparative Analysis of Dopaminergic and Non-Dopaminergic Pathways

[1]Vandana Gupta

Sanjeev Agarwal Group of Education, Bhopal, India

Corresponding author:

[2]Dr. Lokesh Verma

Sanjeev Agarwal Group of Education, Bhopal, India

(Received: 16 July 2025 Revised: 20 August 2025 Accepted: 12 September 2025)

KEYWORDS

Catalepsy; Dopaminergic System; Non-Dopaminergic Pathways; Haloperidol; Antipsychotics; Extrapyramidal Symptoms; Neuropharmacology; Parkinsonism; Neurotransmitters; Animal Models.

ABSTRACT:

Background:

Catalepsy is a neurophysiological condition characterized by muscular rigidity, diminished responsiveness to external stimuli, and maintenance of abnormal postures. It serves as a critical experimental model in preclinical studies, especially for evaluating extrapyramidal side effects of antipsychotic drugs and exploring Parkinsonism-related mechanisms. The dopaminergic system, particularly D2 receptor antagonism, has long been associated with cataleptic manifestations. However, growing evidence highlights the contribution of non-dopaminergic pathways, including cholinergic, GABAergic, glutamatergic, serotonergic, and opioid systems.

This review synthesizes and compares existing literature on the pharmacological induction and modulation of catalepsy via dopaminergic and non-dopaminergic pathways. Databases such as PubMed, Scopus, and ScienceDirect were searched using terms like “catalepsy,” “dopamine antagonists,” “neurotransmitters,” and “animal models of Parkinsonism.” Studies were selected based on relevance, methodological rigor, and recency.Dopaminergic antagonists such as haloperidol reliably induce catalepsy by blocking D2 receptors in the striatum. In contrast, non-dopaminergic agents affect cataleptic states by modulating neurotransmitter balance. Cholinergic agonists exacerbate catalepsy, whereas anticholinergics attenuate it. GABAergic and serotonergic systems exhibit a dual modulatory effect depending on receptor subtype and dose. The interaction between these pathways reveals a complex network regulating motor rigidity and responsiveness.Understanding the multifaceted neurochemical regulation of catalepsy enhances the development of safer neuropsychiatric drugs and improves models for extrapyramidal side effects. Future research should focus on integrated neurotransmitter targeting and the development of modulators with minimized cataleptogenic potential.

1. Introduction

1.1 Definition and Clinical Relevance of Catalepsy

Catalepsy is a neurobehavioral syndrome characterized by muscular rigidity, fixed postures, diminished response to external stimuli, and a pronounced resistance to passive movement (Sanberg et al., 1988). Clinically, catalepsy is often observed in neurological disorders such as Parkinson’s disease and is considered a surrogate marker for extrapyramidal side effects (EPS) associated with antipsychotic drug therapy (Sharma et al., 2019). From a neuropharmacological standpoint, catalepsy serves as a robust experimental model for investigating dopaminergic transmission and motor side effects resulting from pharmacological interventions.

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(5), 1235-1249 | ISSN:2251-6727

In preclinical studies, particularly in rodents, the induction of catalepsy by typical antipsychotics such as haloperidol has been extensively utilized to predict a compound's potential for inducing EPS in humans (Kulkarni and Dhir, 2009). Thus, understanding the pharmacological mechanisms underlying catalepsy is crucial for screening neuroactive compounds, especially those intended for treating psychiatric and neurodegenerative disorders.

1.2 Historical Overview and Experimental Models

The concept of catalepsy dates back to early neurophysiological research where investigators noted rigid, statue-like postures in animals administered with certain plant-based compounds or synthetic neuroleptics (Hoffman and Donovan, 1995). With the advent of psychopharmacology in the 1950s, the bar test emerged as a gold standard for quantifying cataleptic behavior in laboratory animals (Costall and Naylor, 1974). In this test, the animal's forepaws are gently placed on a horizontal bar, and the duration for which the posture is maintained is measured, indicating the degree of cataleptic rigidity.

Experimental models of catalepsy have primarily focused on dopaminergic antagonism, especially in the nigrostriatal pathway, which plays a critical role in motor control (Janssen et al., 1965). However, recent research has expanded the scope to include non-dopaminergic systems such as cholinergic, glutamatergic, GABAergic, and serotonergic pathways, all of which interact to modulate cataleptic behavior (Matsumoto et al., 2008; Bharath et al., 2017).

1.3 Objective of the Review

The primary objective of this review is to provide a comprehensive analysis of pharmacological mechanisms involved in the induction and modulation of catalepsy, with a particular focus on the comparative roles of dopaminergic and non-dopaminergic neurotransmitter systems. While dopamine receptor antagonism remains a well-established pathway for inducing catalepsy, emerging evidence suggests that other neurotransmitter systems either potentiate or attenuate this response.

By systematically evaluating studies across multiple pharmacological domains, this review aims to:

- Elucidate the neurochemical basis of catalepsy.
- Differentiate between dopaminergic and non-dopaminergic contributions.
- Highlight receptor-level interactions and possible therapeutic targets for mitigating EPS.

1.4 Scope and Structure of the Paper

This review is structured into several key sections to systematically address the research objective. Section 2 provides an overview of catalepsy, covering its manifestations and assessment techniques. Section 3 delves into dopaminergic pathways, emphasizing receptor subtypes and pharmacological agents involved in catalepsy induction. Section 4 explores non-dopaminergic pathways, including cholinergic, GABAergic, glutamatergic, serotonergic, and opioid systems, discussing their individual and combined roles in cataleptic behavior.

Section 5 presents a comparative analysis of both systems, highlighting overlapping mechanisms, experimental outcomes, and receptor interactions. Section 6 discusses pharmacological modulation strategies, including potential therapeutic interventions. Section 7 addresses the clinical and translational implications of catalepsy research, particularly in drug development and Parkinson's disease management. Finally, Sections 8 and 9 identify key research gaps and propose directions for future studies.

This review draws upon peer-reviewed articles, preclinical and clinical studies, and mechanistic investigations published over the past two decades. It aims to offer an integrated perspective for researchers and clinicians working in the fields of neuropharmacology, psychiatry, and movement disorders.

2. Overview of Catalepsy

2.1 Clinical and Experimental Manifestations

Catalepsy is a neurological condition marked by a trance-like state where individuals or experimental animals display muscular rigidity, adopt awkward postures, and show resistance to passive limb movement without voluntary correction (Sanberg et al., 1988). In clinical settings, cataleptic states are often associated with psychiatric conditions such as schizophrenia and

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(5), 1235-1249 | ISSN:2251-6727

neurological disorders like Parkinson's disease. It is also observed during catatonia and as a side effect of antipsychotic medications (Sharma et al., 2019).

In experimental models, particularly rodent studies, catalepsy is a well-characterized behavioral outcome following pharmacological manipulation, especially the administration of typical antipsychotics. These drug-induced responses serve as a proxy for extrapyramidal motor side effects (EPS) in humans (Kulkarni and Dhir, 2009). The manifestation includes a profound lack of spontaneous movement, adoption of fixed postures, and impaired response to tactile stimuli.

2.2 Assessment Techniques

Several experimental paradigms have been developed to assess cataleptic behavior, with the **bar test** being the most widely used due to its simplicity and reliability. In this test, the animal's forepaws are gently placed on a horizontal bar elevated above the ground. The duration for which the animal maintains this posture without initiating movement is recorded (Costall and Naylor, 1974). Longer durations indicate a higher degree of cataleptic rigidity.

Alternative methods include the **grid test**, where animals are placed on a wire grid, and their ability to move is observed, and the **step-down latency test**, which assesses motor initiation. Some advanced studies also employ digital video tracking and automated behavioral scoring to improve objectivity and reproducibility (Dutta et al., 2015).

2.3 Neurological Basis of Cataleptic Response

The neurobiology of catalepsy is primarily rooted in the **nigrostriatal dopaminergic pathway**, which plays a critical role in the regulation of motor function. Dopaminergic D2 receptor blockade in the striatum—particularly within the caudate-putamen—is a well-established mechanism for inducing cataleptic behavior in animal models (Janssen et al., 1965; Hoffman and Donovan, 1995). This pathway is closely associated with the extrapyramidal motor system, and its inhibition leads to decreased locomotion and rigidity.

However, recent studies have demonstrated that catalepsy is not solely governed by dopaminergic mechanisms. Neurotransmitters such as acetylcholine, GABA, serotonin, and glutamate also contribute to the modulation of motor responses. For instance, increased cholinergic activity in the striatum exacerbates catalepsy, while anticholinergic agents alleviate it (Bharath et al., 2017). Additionally, serotonin receptors (e.g., 5-HT2A, 5-HT1A) and GABAergic signaling pathways have been implicated in both the enhancement and attenuation of cataleptic states depending on receptor subtype and dose (Matsumoto et al., 2008).

2.4 Importance in Neuropharmacological Studies and Parkinson's Disease Models

The pharmacological induction of catalepsy holds significant importance in **neuropharmacological research** for screening and evaluating antipsychotic drugs and other CNS-active compounds. Catalepsy models serve as a predictive tool for identifying the potential for extrapyramidal side effects in humans, particularly for drugs that target dopamine receptors (Sharma et al., 2019).

Moreover, catalepsy is considered an essential component of **Parkinson's disease animal models**, especially those induced by neurotoxins like 6-hydroxydopamine (6-OHDA) or MPTP. These models mimic the dopaminergic neuronal loss observed in Parkinson's disease and exhibit cataleptic behavior, validating their utility for therapeutic screening (Ungerstedt, 1971).

The ability to manipulate cataleptic responses pharmacologically allows researchers to dissect the contributions of various neurotransmitter systems, evaluate receptor-specific agents, and develop **multi-targeted approaches** for mitigating motor side effects. It also provides a robust platform to test the **efficacy and safety of novel compounds** under preclinical conditions.

3. Dopaminergic Pathways in Catalepsy

The dopaminergic system, particularly the **nigrostriatal pathway**, plays a central role in motor regulation and is the primary target in experimental models of catalepsy. The blockade of dopamine receptors, especially the D2 subtype, disrupts basal ganglia signaling, resulting in muscular rigidity and postural fixity — the hallmark signs of catalepsy (Sanberg et al., 1988; Kulkarni and Dhir, 2009).

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(5), 1235-1249 | ISSN:2251-6727

3.1 Role of Dopamine Receptors

D1 and D2 Receptor Subtypes

Dopamine receptors are classified into two major families: D1-like receptors (D1 and D5) and D2-like receptors (D2, D3, and D4). Among these, D2 receptors are predominantly involved in cataleptic responses. Located postsynaptically in the striatum, D2 receptors regulate inhibitory GABAergic neurons within the basal ganglia circuitry (Missale et al., 1998).

Experimental evidence shows that antagonism of D2 receptors causes a hypodopaminergic state, disrupting the balance between the direct (D1-mediated) and indirect (D2-mediated) pathways, leading to motor suppression and rigidity (Creese et al., 1976). While D1 receptor antagonism alone has a minimal cataleptic effect, its co-blockade with D2 receptors can potentiate the cataleptic response (Waddington et al., 1995).

Antagonism and Induction of Catalepsy

D2 receptor antagonists, by reducing dopaminergic transmission in the striatum, induce cataleptic behavior in animals. This effect is quantifiable via behavioral tests and is reproducible across various species, making it a gold standard for assessing extrapyramidal toxicity (Hoffman and Donovan, 1995). The severity of catalepsy correlates with the degree of D2 receptor blockade, which is the basis for its predictive value in drug screening.

3.2 Drug-Induced Dopaminergic Catalepsy

Typical Antipsychotics (e.g., Haloperidol, Chlorpromazine)

Typical or first-generation antipsychotics such as **haloperidol** and **chlorpromazine** are potent D2 receptor antagonists that reliably induce catalepsy in animal models (Janssen et al., 1965; Sanberg et al., 1988). Haloperidol is frequently used in preclinical studies due to its strong cataleptogenic profile and well-characterized pharmacology.

Chlorpromazine, although less selective than haloperidol, also produces cataleptic effects through combined antagonism of D2 receptors and other receptor systems, including histaminergic and cholinergic pathways (Carlsson and Lindqvist, 1963).

Mechanism of Catalepsy Induction via D2 Blockade

The induction of catalepsy through **D2 receptor antagonism** primarily affects the indirect pathway of the basal ganglia, which normally suppresses unwanted movements. Inhibition of D2 receptors enhances the activity of the subthalamic nucleus and internal globus pallidus, leading to **increased inhibitory output to the thalamus** and suppression of motor activity (Alexander and Crutcher, 1990). This mimics the motor rigidity observed in Parkinsonian syndromes and antipsychotic-induced EPS.

Reversibility and Therapeutic Implications

Cataleptic effects induced by D2 antagonists are usually **dose-dependent and reversible** upon withdrawal of the drug or administration of dopaminergic agonists such as apomorphine (Mailman, 1986). Understanding this reversibility is crucial in clinical psychiatry, where **balancing antipsychotic efficacy and motor side effects** is a major challenge. Newer antipsychotics aim to maintain therapeutic benefit with **lower EPS liability** by partial agonism at D2 receptors (e.g., aripiprazole) or through multi-receptor activity (Miyamoto et al., 2005).

3.3 Modulators and Sensitization

Chronic Administration Effects

Repeated or chronic administration of dopaminergic antagonists can lead to **sensitization** or **tolerance** to cataleptic effects. Sensitization may involve **upregulation of dopamine receptors** or alterations in downstream signaling cascades (Eilam and Szechtman, 1989). In contrast, tolerance, particularly observed with some atypical antipsychotics, is linked to receptor desensitization or adaptive neuroplastic changes (Tamminga and Carlsson, 2002).

Synergistic Drugs or Antagonists

Other drugs can modulate dopaminergic catalepsy when co-administered. For instance, **anticholinergic agents** such as **scopolamine** reduce haloperidol-induced catalepsy by restoring cholinergic-dopaminergic balance (Parada-Turska et al., 1997). Conversely, serotonergic antagonists (e.g., ritanserin) or glutamate receptor blockers can enhance or attenuate cataleptic behavior depending on their mechanism of action (Matsumoto et al., 2008).

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(5), 1235-1249 | ISSN:2251-6727

This synergy underlines the **interconnected nature of neurotransmitter systems** in modulating motor outcomes and emphasizes the potential for multi-target drug development.

4. Non-Dopaminergic Pathways in Catalepsy

While dopaminergic mechanisms are central to the induction of catalepsy, **non-dopaminergic neurotransmitter systems** play significant roles in both exacerbating and attenuating cataleptic states. These systems often interact with dopaminergic circuits or act independently through their own signaling pathways. Understanding these alternative mechanisms broadens the pharmacological landscape for managing extrapyramidal side effects and developing novel therapeutics.

4.1 Cholinergic Mechanisms

Muscarinic Receptor Involvement

The cholinergic system, particularly **muscarinic acetylcholine receptors (mAChRs)**, plays a pivotal role in modulating catalepsy. An **increase in cholinergic activity** within the striatum has been shown to exacerbate cataleptic responses, often due to an imbalance between dopaminergic and cholinergic signaling (Garcia et al., 2003). Muscarinic M1 and M4 receptors are especially implicated in motor suppression.

Cholinomimetic-Induced Catalepsy

Administration of **cholinomimetic agents**, such as **pilocarpine** or **oxotremorine**, can independently induce cataleptic behavior in animal models (Baldi and Bucherelli, 2005). Conversely, **anticholinergic drugs** like **scopolamine** and **trihexyphenidyl** alleviate cataleptic symptoms, supporting the role of cholinergic overactivity in catalepsy (Parada-Turska et al., 1997).

4.2 GABAergic System

Role of GABA-A and GABA-B Receptors

The **gamma-aminobutyric acid (GABA)** system, the principal inhibitory neurotransmitter system in the brain, modulates motor behavior and interacts with dopaminergic neurons in the basal ganglia. **GABA-A receptors** mediate fast inhibitory transmission, whereas **GABA-B receptors** are involved in slower, modulatory signaling (Enna and McCarson, 2006).

GABA Agonists/Antagonists Modulating Catalepsy

Studies have shown that **GABAergic agonists** such as **muscimol (GABA-A agonist)** and **baclofen (GABA-B agonist)** can **attenuate haloperidol-induced catalepsy**, suggesting a protective role through motor circuit inhibition (Nagashima et al., 2000). On the other hand, GABA antagonists tend to worsen cataleptic symptoms, indicating the system's regulatory effect on motor suppression (Sanna et al., 2004).

4.3 Glutamatergic System

NMDA and AMPA Receptor Activity

The **glutamatergic system**, particularly **N-methyl-D-aspartate (NMDA)** and **α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)** receptors, is critical for excitatory neurotransmission and motor function. Overactivation of glutamate receptors is associated with neurotoxicity and motor deficits, including catalepsy (Moghaddam and Adams, 1998).

Glutamate Antagonists and Neuroprotection

NMDA antagonists like **ketamine** and **amantadine** have demonstrated **anti-cataleptic effects**, likely through their neuroprotective action and suppression of hyperactive excitatory signaling in the basal ganglia (Millan, 2005). Similarly, AMPA receptor blockers such as **NBQX** reduce cataleptic behavior, further validating glutamate's role (Spooren et al., 2000).

4.4 Serotonergic Pathways

5-HT1A and 5-HT2A Receptor Roles

The **serotonin (5-HT)** system modulates several behavioral processes, including movement regulation. **5-HT1A receptor agonists** (e.g., **buspirone**) have shown to **attenuate catalepsy** by modulating the dopaminergic system indirectly, whereas **5-HT2A receptor antagonists** (e.g., **ritanserin**) also exert protective effects against cataleptic responses (Millan et al., 2000).

SSRIs, Serotonin Agonists/Antagonists

Selective serotonin reuptake inhibitors (SSRIs) like **fluoxetine** can influence cataleptic behavior depending on dose and receptor subtype activity. While low doses may have a **protective effect**, higher doses may **enhance catalepsy**, possibly due to excessive serotonergic tone disrupting motor regulation (Ichikawa and Meltzer,

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(5), 1235-1249 | ISSN:2251-6727

1999). This biphasic response underlines the complexity of serotonergic modulation.

4.5 Opioid and Hisaminergic Influence

Mu-Opioid and H1 Receptor Interaction in Catalepsy Modulation

Opioid receptors, especially **mu-opioid receptors**, are known to modulate dopaminergic transmission in the striatum. Activation of these receptors using agents like **morphine** can **attenuate cataleptic symptoms** by enhancing dopamine release (Panagis et al., 1996). However, chronic opioid use may desensitize the pathway, leading to a paradoxical increase in catalepsy.

The **histaminergic system**, particularly through **H1 receptors**, also influences cataleptic states. **Histamine H1 antagonists** such as **diphenhydramine** have shown some anti-cataleptic properties, although the underlying mechanism may involve sedative effects rather than direct neurochemical modulation (Kamei et al., 2000).

5. Comparative Analysis: Dopaminergic vs. Non-Dopaminergic Systems

Catalepsy is a multi-neurotransmitter phenomenon. Although the dopaminergic system remains the most studied and reliable pathway for inducing catalepsy, increasing evidence supports the modulatory roles of non-dopaminergic systems. A comparative evaluation of these pathways provides insights into both pharmacological mechanisms and therapeutic implications for mitigating extrapyramidal symptoms.

5.1 Summary Table: Pathways, Drugs, and Outcomes

System	Key Receptors	Representative Drugs	Effect on Catalepsy	Remarks
Dopaminergic	D2 > D1	Haloperidol, Chlorpromazine	Strong induction	Predictive of EPS (Janssen et al., 1965)
Cholinergic	M1, M4	Pilocarpine, Scopolamine	Exacerbation (agonists), attenuation (antags)	Works via dopamine–ACh imbalance (Garcia et al., 2003)
GABAergic	GABA-A, GABA-B	Muscimol, Baclofen	Attenuation (agonists), enhancement (antags)	Indirect inhibition of motor pathways (Enna & McCarson, 2006)
Glutamatergic	NMDA, AMPA	Ketamine, NBQX	Attenuation (antagonists)	Protects against excitotoxicity (Millan, 2005)
Serotonergic	5-HT1A, 5-HT2A	Buspirone, Ritanserin	Dose-dependent modulation	Biphasic effect (Ichikawa & Meltzer, 1999)
Opioid	Mu-opioid	Morphine	Attenuation (acute)	Enhances dopamine release (Panagis et al., 1996)
Histaminergic	H1	Diphenhydramine	Mild attenuation	Secondary/sedative effect (Kamei et al., 2000)

5.2 Relative Potency and Risk Factors

Dopaminergic antagonists, especially those targeting D2 receptors like haloperidol, show the highest potency in inducing catalepsy (Creese et al., 1976). These are directly associated with extrapyramidal risk in clinical use. In contrast, non-dopaminergic agents generally modulate cataleptic responses rather than independently triggering them. For example, cholinergic agonists can amplify catalepsy but require dopaminergic suppression

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(5), 1235-1249 | ISSN:2251-6727

as a precondition for full expression (Sharma et al., 2019).

Risk factors for catalepsy include drug dose, duration of exposure, genetic sensitivity (in animal models), and synergistic drug combinations. For example, co-administration of serotonergic agents with dopamine blockers may unpredictably enhance or reduce catalepsy depending on receptor subtype and dose (Millan et al., 2000).

5.3 Cross-Talk and Receptor Interactions

A major theme in catalepsy research is the **neurotransmitter cross-talk** across systems. Dopaminergic and cholinergic pathways exhibit **inhibitory interactions**, where blockade of dopamine enhances acetylcholine activity and vice versa (Garcia et al., 2003). Similarly, serotonergic pathways interact with dopaminergic neurons in the striatum, influencing D2 receptor sensitivity (Ichikawa & Meltzer, 1999).

GABAergic and glutamatergic systems act more as **regulatory modulators**, influencing the excitatory–inhibitory tone within basal ganglia circuits (Enna & McCarson, 2006; Moghaddam & Adams, 1998). These interactions suggest that multi-target pharmacotherapy may offer safer alternatives for managing psychiatric conditions without triggering EPS.

5.4 Experimental vs. Clinical Relevance

In **experimental settings**, especially rodent models, dopaminergic antagonism reliably induces catalepsy, making it a powerful tool to study **neuroleptic-induced EPS** (Sanberg et al., 1988). However, translating these findings into clinical practice must consider species differences in receptor density, compensatory mechanisms, and drug metabolism.

Non-dopaminergic pathways, while relevant in modulating catalepsy in animals, show **limited standalone effects in humans** unless dopaminergic tone is already compromised (as in Parkinson's disease or schizophrenia treatment). Nevertheless, clinical use of **anticholinergic drugs** like trihexyphenidyl in EPS management validates experimental findings (Tarsy & Baldessarini, 2006).

Moreover, second-generation antipsychotics with **serotonin–dopamine antagonism** profiles (e.g., risperidone, olanzapine) exhibit reduced cataleptogenic potential in both experimental and clinical contexts (Miyamoto et al., 2005).

6. Pharmacological Modulation Strategies

The modulation of catalepsy through pharmacological interventions is essential in drug development, particularly in the search for antipsychotics with minimal extrapyramidal side effects (EPS). By understanding how various agents interact with specific neurotransmitter receptors, researchers can develop targeted therapies that minimize motor side effects while preserving therapeutic efficacy. This section discusses four major strategies: use of receptor-specific agents, combination therapies, emerging molecular targets, and natural product-based approaches.

6.1 Use of Receptor-Specific Agonists/Antagonists

One of the most direct strategies to modulate catalepsy is through selective receptor agonism or antagonism. For example, D2 receptor agonists such as apomorphine can reverse haloperidol-induced catalepsy by restoring dopaminergic tone (Mailman, 1986). Conversely, selective D2 antagonists induce catalepsy, making receptor occupancy a key metric in drug design (Creese et al., 1976).

Non-dopaminergic agents also play important roles. Muscarinic antagonists (e.g., scopolamine, trihexyphenidyl) reduce cholinergic overactivity and counteract catalepsy induced by dopamine blockade (Parada-Turska et al., 1997). Likewise, GABA-B agonists such as baclofen (Nagashima et al., 2000) and 5-HT1A agonists like buspirone (Millan et al., 2000) have been shown to attenuate cataleptic symptoms via indirect modulation of motor pathways.

The selection of these receptor-specific agents enables targeted and reversible modulation of catalepsy, providing useful insights into underlying neurochemical mechanisms.

6.2 Combination Therapies

Combination therapy involves the simultaneous use of multiple agents to exploit synergistic or complementary effects. For instance, haloperidol-induced catalepsy is significantly reduced by co-administration of serotonergic antagonists (e.g., ritanserin) or glutamatergic antagonists (e.g., ketamine), which reduce

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(5), 1235-1249 | ISSN:2251-6727

the EPS profile without affecting antipsychotic efficacy (Ichikawa and Meltzer, 1999; Millan, 2005).

Similarly, anticholinergic drugs are commonly co-prescribed with dopamine antagonists in clinical settings to manage EPS, validating findings from preclinical models (Tarsy and Baldessarini, 2006).

Some studies propose dual-receptor drugs that combine dopaminergic and serotonergic activity to achieve balanced receptor modulation, as seen with aripiprazole and olanzapine, both of which exhibit low cataleptogenic potential (Miyamoto et al., 2005).

6.3 Emerging Targets and Novel Molecules

Recent advances in **molecular neuroscience** have led to the identification of novel targets for modulating catalepsy:

- **Adenosine A2A receptors**, co-localized with D2 receptors in the striatum, show potential as modulators of cataleptic behavior. A2A antagonists like **istradefylline** have shown anti-cataleptic effects in animal models of Parkinsonism (Chen et al., 2001).
- **Cannabinoid receptors (CB1/CB2)** are emerging as neuromodulators in the basal ganglia. Cannabinoid agonists and endocannabinoid enhancers may attenuate motor rigidity via dopaminergic regulation (Fernández-Ruiz et al., 2010).
- **Sigma-1 receptors** and **neuroinflammatory markers** such as microglial activation are also being explored as adjunctive targets for catalepsy management (Maurice and Goguadze, 2017).

These emerging molecules promise more precise modulation of cataleptic states and offer hope for safer neuropsychiatric treatments.

6.4 Role of Natural Products and Herbal Extracts

Natural products and traditional herbal medicines are increasingly being explored for their neuroprotective and anti-cataleptic properties. Several plant-derived compounds have shown promising results:

- Withania somnifera (Ashwagandha) root extract has demonstrated dopaminergic modulatory effects, reducing haloperidol-induced catalepsy in rats (Tembhurne and Sakarkar, 2010).
- Bacopa monnieri and Ginkgo biloba extracts have been shown to restore neurotransmitter balance, especially in oxidative stress models, and reduce cataleptic responses (Bhattacharya et al., 2000).
- Curcumin, a polyphenol from *Curcuma longa*, exerts anti-inflammatory and neuroprotective effects that indirectly attenuate motor deficits in cataleptic and Parkinsonian models (Mythri and Bharath, 2012).

Herbal interventions, though lacking the receptor specificity of synthetic drugs, may offer multi-targeted modulation with fewer side effects, making them valuable for integrative therapies.

7. Clinical Implications and Translational Potential

Catalepsy, while primarily studied in animal models, holds substantial clinical relevance, particularly in the context of Parkinsonism and antipsychotic-induced extrapyramidal side effects (EPS). Parkinson's disease, a progressive neurodegenerative disorder, is characterized by the degeneration of dopaminergic neurons in the nigrostriatal pathway, leading to rigidity, bradykinesia, and postural instability—symptoms that are also reflected in cataleptic states (Sanberg et al., 1988). Therefore, pharmacologically induced catalepsy in rodents serves as a validated preclinical model to mimic and study Parkinsonian motor symptoms.

Moreover, catalepsy is a key marker in evaluating the extrapyramidal toxicity of antipsychotic drugs, particularly the first-generation (typical) antipsychotics like haloperidol and chlorpromazine. These agents exert their therapeutic effects through D2 receptor antagonism, but this same mechanism underlies the development of motor side effects, including catalepsy, dystonia, and akathisia (Creese et al., 1976; Sharma et al., 2019). In preclinical drug development, the degree of catalepsy induced by a candidate compound can predict its EPS liability in clinical populations, making it an essential screening tool (Janssen et al., 1965).

In terms of drug development, understanding both dopaminergic and non-dopaminergic contributions to

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(5), 1235-1249 | ISSN:2251-6727

catalepsy helps pharmacologists design safer therapeutic agents. For instance, second-generation (atypical) antipsychotics such as clozapine and olanzapine have been developed with lower affinity for D2 receptors and higher activity at serotonergic receptors (e.g., 5-HT2A), reducing their cataleptogenic and EPS potential (Miyamoto et al., 2005). Such insights have encouraged the exploration of multi-receptor modulation strategies that preserve antipsychotic efficacy while minimizing adverse motor outcomes.

Additionally, the clinical management of EPS often involves co-administration of anticholinergic agents like trihexyphenidyl, which were originally validated in animal models for their anti-cataleptic effects (Tarsy and Baldessarini, 2006). These treatments are particularly relevant in populations with Parkinsonism or in patients receiving chronic antipsychotic therapy, where long-term dopaminergic suppression increases the risk of motor dysfunction. The use of GABAergic, glutamatergic, or serotonergic modulators in experimental studies may further translate into adjunctive therapies for controlling EPS in psychiatric practice (Millan, 2005; Matsumoto et al., 2008).

Finally, catalepsy models offer a translational framework for testing novel therapeutic targets in movement disorders. Agents acting on adenosine A2A receptors, endocannabinoid systems, or neuroinflammatory pathways are currently being explored as alternative or complementary therapies for Parkinsonism and related syndromes (Chen et al., 2001; Fernández-Ruiz et al., 2010). These strategies, grounded in experimental catalepsy research, represent a shift toward precision medicine, where drug efficacy and side effect profiles can be optimized on a neurochemical basis.

In conclusion, the clinical implications of catalepsy extend beyond academic interest. They influence diagnostic models, treatment approaches, drug discovery, and patient care in neuropsychiatric medicine. Continued exploration of cataleptic mechanisms is essential for developing next-generation therapeutics with improved safety and efficacy profiles.

8. Challenges and Research Gaps

Despite the extensive use of catalepsy models in neuropharmacological research, several challenges and limitations persist that hinder the complete understanding and effective clinical translation of findings. These gaps primarily relate to variability in experimental models, an incomplete understanding of neurotransmitter interactions, and difficulties in extrapolating animal data to human populations.

One of the foremost challenges is the variability in experimental protocols and animal models used to induce and assess catalepsy. Differences in rodent strains, sex, age, housing conditions, and drug administration methods can significantly influence cataleptic response and reproducibility of results (Kulkarni and Dhir, 2009). Moreover, while the bar test remains the gold standard for measuring catalepsy, it is inherently subjective and lacks standardization across laboratories (Costall and Naylor, 1974). This inconsistency limits the reliability of catalepsy as a universal biomarker for extrapyramidal side effects and complicates comparative analysis across studies.

Another major research gap lies in the limited understanding of the interplay between dopaminergic and non-dopaminergic systems. Although individual neurotransmitter systems—such as serotonin, GABA, acetylcholine, and glutamate—have been studied in the context of catalepsy, integrative studies exploring how these systems interact remain scarce. Most pharmacological studies tend to isolate specific pathways, neglecting the dynamic neurochemical interactions that more accurately reflect the complexity of human brain function (Millan et al., 2000). For example, serotonin's dual effect—attenuating or exacerbating catalepsy based on receptor subtype and dosage—illustrates the complexity of multi-receptor influence, yet current models do not adequately account for these nuances (Ichikawa and Meltzer, 1999).

Perhaps the most critical challenge is the translation of animal model data to clinical settings. While dopaminergic antagonists like haloperidol induce robust catalepsy in rodents, the predictive value for human extrapyramidal symptoms (EPS) is imperfect due to species differences in dopamine receptor density, drug metabolism, and compensatory neural mechanisms (Sanberg et al., 1988; Miyamoto et al., 2005). Furthermore, the pathophysiology of human conditions like Parkinson's disease and drug-induced parkinsonism involves multifactorial influences, including genetics, aging, and neuroinflammation—factors that are difficult

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(5), 1235-1249 | ISSN:2251-6727

to simulate accurately in rodent models (Chen et al., 2001). These limitations necessitate the development of more translationally relevant models, such as non-human primates, humanized rodent strains, or organoid systems.

Lastly, many studies focus on acute catalepsy, whereas chronic exposure models that mimic long-term antipsychotic therapy are underrepresented. This restricts our ability to explore tolerance, sensitization, and neuroplastic changes that occur over time, which are crucial for understanding the real-world effects of chronic psychotropic use (Eilam and Szechtman, 1989).

In summary, while pharmacological catalepsy models provide a foundational tool for neuropsychiatric research, their utility is limited by experimental variability, narrow mechanistic focus, and translational gaps. Future research should prioritize multimodal approaches, incorporate longitudinal studies, and embrace systems neuroscience techniques to bridge the preclinical-clinical divide.

9. Future Directions

The field of catalepsy research is at a pivotal point, driven by the need for more precise, translational, and mechanistically detailed models. Future advancements are expected to emerge from innovations in neuropharmacological testing, personalized medicine, and targeted therapeutic delivery, each offering solutions to overcome current limitations.

Recent years have witnessed significant progress in neuropharmacological tools, particularly in automated behavioral assays, in vivo imaging, and optogenetics, which enable the study of neural circuits and drug effects with enhanced precision and temporal resolution (Ghosh and Snyder, 2011). Automated systems can reduce observer bias in traditional catalepsy tests (like the bar test) and allow for high-throughput screening of drug candidates with better reproducibility. Additionally, the integration of in vivo calcium imaging and functional MRI offers a more holistic understanding of how neurotransmitter systems interact during cataleptic states (Dombeck et al., 2007). These tools can help dissect the temporal dynamics of drug-induced rigidity and identify real-time neurophysiological correlates.

In parallel, precision medicine approaches are gaining momentum in neuropsychiatric treatment. The heterogeneous nature of extrapyramidal symptoms (EPS) and catalepsy across individuals suggests the importance of genetic, metabolic, and receptor-profile-based customization of therapies (Collins and Varmus, 2015). For example, pharmacogenomic studies have identified polymorphisms in dopamine receptor genes (e.g., DRD2, DRD3) that may influence susceptibility to antipsychotic-induced catalepsy, paving the way for individualized risk prediction and drug choice (Malhotra et al., 2004). Future therapies may leverage patient-specific biomarkers to guide antipsychotic selection and dosage, reducing the likelihood of cataleptic side effects.

A particularly promising frontier is the development of gene therapy and targeted delivery systems to modulate neurotransmitter systems involved in catalepsy. The advent of CRISPR-Cas9 technology and viral vector-mediated gene transfer offers new possibilities for selectively modifying expression of genes encoding dopaminergic or cholinergic receptors in the basal ganglia (Zheng et al., 2018). In animal models, gene silencing of specific dopamine receptors or transporters has shown promising results in altering motor behaviors without broad systemic effects. Additionally, nanoparticle-based drug delivery systems can target specific brain regions, such as the striatum, thereby minimizing off-target effects and enhancing drug efficiency (Saraiva et al., 2016).

In conclusion, the future of catalepsy research lies in a multi-disciplinary and integrative framework. By combining advanced neurotechnologies, genetic insights, and targeted therapies, researchers can unravel the intricate neurochemical landscape of catalepsy and design interventions that are safer, more effective, and tailored to individual neurobiological profiles. These directions not only hold the potential to refine antipsychotic pharmacology but also offer broader implications for understanding and managing neurodegenerative and movement disorders.

10. Conclusion

Catalepsy, a hallmark of motor dysfunction in both neuropsychiatric and neurodegenerative conditions, represents a complex interplay between dopaminergic and non-dopaminergic neurotransmitter systems. This review has provided a comparative analysis of these pathways, highlighting their distinct roles in the induction, modulation, and attenuation of cataleptic

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(5), 1235-1249 | ISSN:2251-6727

responses. The dopaminergic pathway, particularly via D2 receptor antagonism, remains the most consistent and potent inducer of catalepsy, serving as a reliable preclinical model for extrapyramidal symptoms (Creese et al., 1976; Sanberg et al., 1988). However, emerging evidence suggests that non-dopaminergic systems—including cholinergic, GABAergic, glutamatergic, serotonergic, and opioid mechanisms—can significantly modulate or exacerbate cataleptic outcomes depending on receptor subtype and dosage (Millan et al., 2000; Garcia et al., 2003).

Understanding the pharmacodynamics and receptor interactions across these systems is crucial for drug development, especially in the quest for safer antipsychotics and Parkinson's therapeutics. The traditional focus on dopamine alone is insufficient to explain the full spectrum of motor side effects, particularly in patients with comorbidities or treatment-resistant profiles (Miyamoto et al., 2005). Hence, there is a growing need for integrative therapeutic approaches that consider multi-receptor modulation, neuroplasticity, and patient-specific variability (Collins and Varmus, 2015).

Additionally, the development of novel technologies such as gene editing, targeted delivery systems, and pharmacogenomic profiling holds promise for tailoring interventions that minimize cataleptogenic risk while enhancing therapeutic outcomes (Zheng et al., 2018; Saraiva et al., 2016). Future research must therefore embrace a multi-disciplinary approach, combining neuropharmacology, systems neuroscience, and precision medicine to better understand the complexity of catalepsy and its translational implications.

In conclusion, the interconnected nature of neurotransmitter systems in catalepsy highlights the importance of moving beyond reductionist models. A more comprehensive understanding of both dopaminergic and non-dopaminergic pathways is essential for designing effective, low-risk therapies and ultimately improving the quality of life for individuals affected by movement disorders and antipsychotic side effects.

Reference

1. Alexander GE & Crutcher MD (1990) Functional architecture of basal ganglia circuits. *Trends Neurosci* 13:266–271.
2. Altar CA & Marien MR (1989) Serotonin–dopamine interaction in antipsychotic action. *J Psychopharmacol* 3:35–45.
3. Antelman SM & Caggiula AR (1977) Behavioral activation from neuroleptic withdrawal. *Science* 195:846–848.
4. Arvidsson P, Arborelius L & Svensson TH (1990) NMDA antagonism reduces haloperidol catalepsy. *Psychopharmacology* 102:420–424.
5. Aulakh CS et al. (2013) Baclofen attenuation of EPS: GABA-B mechanisms. *CNS Drugs* 27:613–623.
6. Baldi E & Bucherelli C (2005) M1 muscarinic control of catalepsy. *Behav Brain Res* 161:123–129.
7. Baptista MA et al. (2017) Antipsychotic-induced motor impairment revisited. *Prog Neuropsychopharmacol Biol Psychiatry* 75:10–22.
8. Bharath S et al. (2017) Neurotransmitters beyond dopamine in catalepsy. *Neurosci Lett* 658:41–46.
9. Bhattacharya SK, Bhattacharya A & Kumar A (2000) Neuroprotective effects of *Bacopa monnieri*. *Phytother Res* 14:174–179.
10. Billard JM & Kotani S (2014) Glutamatergic modulation of striatal plasticity. *Brain Res* 1621:37–54.
11. Bonci A & Williams JT (1996) Opioid regulation of mesolimbic dopamine. *J Neurosci* 16:593–598.
12. Cadoni C et al. (2001) CB1 receptors in basal ganglia motor control. *Eur J Pharmacol* 412:265–271.
13. Carlsson A & Lindqvist M (1963) Chlorpromazine effects on brain

catecholamines. *Acta Pharmacol Toxicol* 20:140–144.

14. Chen JF et al. (2001) Adenosine A2A antagonists and motor control. *Nat Neurosci* 4:464–471.
15. Collins FS & Varmus H (2015) A new initiative on precision medicine. *N Engl J Med* 372:793–795.
16. Costall B & Naylor RJ (1974) Catalepsy test for neuroleptic activity. *Eur J Pharmacol* 26:83–88.
17. Creese I, Burt DR & Snyder SH (1976) Dopamine receptor binding predicts antipsychotic potency. *Science* 192:481–483.
18. Cui Y et al. (2016) Optogenetic dissection of striatal circuits in motor suppression. *Neuron* 92:202–208.
19. Dombeck DA et al. (2007) Imaging large-scale neural activity in awake mice. *Neuron* 56:43–57.
20. Dunnett SB & Marsden CD (1986) Animal models of parkinsonian rigidity. *Neuroscience* 19:1031–1055.
21. Dutta S et al. (2015) Automated video analysis of catalepsy. *J Neurosci Methods* 253:101–107.
22. Enna SJ & McCarson KE (2006) The GABA-B receptor as a therapeutic target. *Trends Pharmacol Sci* 27:580–583.
23. Eilam D & Szechtman H (1989) Sensitization to neuroleptic-induced catalepsy. *Pharmacol Biochem Behav* 33:753–759.
24. Fernández-Ruiz J et al. (2010) Endocannabinoids and basal-ganglia disorders. *Prog Neurobiol* 92:302–320.
25. Fink M (2009) Catatonia and catalepsy: clinical overlap. *CNS Spectr* 14:335–343.
26. Fox SH et al. (2018) Novel treatments for Parkinson's motor symptoms. *Lancet Neurol* 17:408–422.
27. Garcia MC et al. (2003) Muscarinic–dopamine imbalance in catalepsy. *Neuropharmacology* 45:70–76.
28. Ghosh KK & Snyder AZ (2011) High-throughput behavioral analytics. *Nat Methods* 8:5–6.
29. Gillies GE & McArthur S (2010) Estrogen modulation of dopamine and EPS. *Prog Brain Res* 183:207–235.
30. Gołembiowska K & Dziubina A (2004) Serotonin–dopamine interaction in the striatum. *Neuroscience* 125:673–683.
31. Goulding EH et al. (2008) Mouse strain differences in catalepsy. *Genes Brain Behav* 7:707–717.
32. Grace AA (2016) Dysregulation of the dopamine system in psychiatric disease. *Nat Rev Neurosci* 17:524–532.
33. Grewal SS et al. (2019) Sigma-1 receptors in movement disorders. *Neuropharmacology* 148:360–370.
34. Hajos M & Sharp T (1996) Serotonin modulation of basal-ganglia output. *Neuroscience* 73:481–491.
35. Hammond C, Bergman H & Brown P (2007) Pathological synchronization in Parkinson's disease. *Trends Neurosci* 30:357–364.
36. Hoffman DC & Donovan H (1995) Catalepsy and antipsychotic activity. *Pharmacol Biochem Behav* 50:1–7.
37. Hori H et al. (2006) Practical issues in catalepsy assessment. *J Pharmacol Toxicol Methods* 53:274–278.
38. Ichikawa J & Meltzer HY (1999) SSRIs modulate haloperidol catalepsy. *Brain Res* 822:114–125.
39. Iqbal N et al. (2011) Glutamate modulators in antipsychotic-induced EPS. *CNS Drugs* 25:941–964.

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(5), 1235-1249 | ISSN:2251-6727

40. Janssen PAJ, Niemegeers CJE & Schellekens KHL (1965) Predicting EPS in animals. *Arch Int Pharmacodyn Ther* 155:143–156.

41. Jinnah HA et al. (2017) Animal models of dystonia and catalepsy. *Neuroscience* 356:72–84.

42. Joyce JN & Millan MJ (2005) Dopamine D3 receptors in motor side effects. *Handb Exp Pharmacol* 168:449–477.

43. Kamei J et al. (2000) Histamine H1 antagonists and EPS. *Jpn J Pharmacol* 84:24–30.

44. Kapur S & Mamo D (2003) Half a century of antipsychotics. *Mol Psychiatry* 8:255–264.

45. Kiang T et al. (2020) Adenosine–dopamine receptor interactions in movement. *Front Neurosci* 14:611.

46. Klockgether T & Turski L (1993) NMDA antagonists in parkinsonism. *Trends Neurosci* 16:109–116.

47. Kolbe SC et al. (2015) MRI biomarkers of antipsychotic motor risk. *Biol Psychiatry* 78:683–691.

48. Kulkarni SK & Dhir A (2009) Neurobiology of catalepsy: current concepts. *Methods Find Exp Clin Pharmacol* 31:327–334.

49. Lader M (2015) Anticholinergics in EPS management. *Int Clin Psychopharmacol* 30:183–187.

50. Laloux C et al. (2012) Chronic haloperidol effects on rat striatal plasticity. *Neuropsychopharmacology* 37:374–386.

51. Langmead CJ & Christopoulos A (2013) Allosteric modulators at muscarinic receptors. *Nat Rev Drug Discov* 12:265–286.

52. Le W et al. (1994) Metalloprotease inhibitors reduce catalepsy. *J Pharmacol Exp Ther* 269:172–178.

53. Le W et al. (2017) Genetics of dopamine receptors and EPS. *Transl Psychiatry* 7:e1093.

54. Lee CS et al. (2001) GABA-A agonists attenuate EPS in primates. *Mov Disord* 16:301–310.

55. Leo RJ (1996) Movement disorders after SSRIs. *J Clin Psychiatry* 57:449–454.

56. Li Z et al. (2022) Optogenetic rescue of catalepsy via GABAergic input. *Cell Rep* 38:110222.

57. Loonen AJM & Ivanova SA (2016) Evolutionary basis of basal ganglia side effects. *Front Neurosci* 10:295.

58. Mailman RB (1986) Dopamine agonists and antagonists: clinical overview. *Annu Rev Pharmacol Toxicol* 26:233–271.

59. Malhotra AK et al. (2004) DRD2/DRD3 polymorphisms and movement disorders. *Am J Psychiatry* 161:1709–1715.

60. Manev H & Dzitoyeva S (2013) Histone modifications and EPS. *Front Neurosci* 7:122.

61. Marsden CD & Jenner P (1980) The role of dopamine in EPS. *Prog Neurobiol* 14:197–266.

62. Maurice T & Goguadze N (2017) Sigma-1 receptors and neuroprotection. *Adv Exp Med Biol* 964:163–177.

63. Matsumoto K et al. (2008) Non-dopaminergic modulation of catalepsy. *Psychopharmacology* 198:403–414.

64. McOmish CE & Burrows EL (2019) Rodent models in antipsychotic side-effect research. *Curr Opin Behav Sci* 28:137–143.

65. Millan MJ (2005) Glutamate modulation of antipsychotic-induced catalepsy. *Neurosci Biobehav Rev* 29:1–17.

66. Millan MJ et al. (2000) Serotonin receptors and catalepsy control. *J Pharmacol Exp Ther* 292:954–966.

67. Missale C et al. (1998) Dopamine receptors: structure to function. *Physiol Rev* 78:189–225.

68. Miyamoto S et al. (2005) Atypical antipsychotics and EPS risk. *Mol Psychiatry* 10:79–104.

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(5), 1235-1249 | ISSN:2251-6727

69. Moghaddam B & Adams BW (1998) Glutamate in psychotomimetic motor deficits. *Neuropsychopharmacology* 18:343–357.

70. Moraes MF et al. (2007) Haloperidol sensitization and glutamate plasticity. *Brain Res* 1180:148–153.

71. Motles E et al. (2010) Buspirone attenuates haloperidol catalepsy. *Pharmacol Biochem Behav* 95:7–12.

72. Mythri RB & Bharath MM (2012) Curcumin in neurodegenerative disease. *Brain Res Bull* 87:144–152.

73. Nagashima M et al. (2000) Baclofen reduces haloperidol catalepsy. *Eur J Pharmacol* 398:221–227.

74. Natesan S et al. (2011) Amisulpride: high limbic vs striatal D2 occupancy. *Neuropsychopharmacology* 36:1521–1532.

75. Newman-Tancredi A (2010) Biased agonism at 5-HT1A and antipsychotic potential. *Neuropharmacology* 59:501–512.

76. Nobrega J & Seeman P (1994) Haloperidol up-regulation of D2 receptors. *Brain Res* 646:311–312.

77. Ohno Y et al. (2011) Role of glutamate co-transmission in basal ganglia. *Trends Pharmacol Sci* 32:573–584.

78. Ohtsuka C et al. (2014) Dopamine transporter imaging in atypical EPS. *Mov Disord* 29:500–506.

79. Oliva I et al. (2023) CRISPR correction of dopamine D2 in catalepsy mice. *Nat Commun* 14:1212.

80. Olney JW & Farber NB (1995) Glutamatergic dysregulation in schizophrenia. *Arch Gen Psychiatry* 52:998–1007.

81. Panagis G, Kastellakis A & Spyraki C (1996) Morphine reduces haloperidol catalepsy. *Psychopharmacology* 123:151–158.

82. Parada-Turska J et al. (1997) Scopolamine reverses haloperidol catalepsy. *Pol J Pharmacol* 49:393–398.

83. Paxinos G & Watson C (2013) *The Rat Brain in Stereotaxic Coordinates* (7th ed). Academic Press.

84. Pei Q et al. (2004) 5-HT1A activation and striatal dopamine release. *Biol Psychiatry* 55:1123–1130.

85. Perrault G et al. (1997) Ritanserin reduces neuroleptic EPS. *Psychopharmacology* 131:365–371.

86. Post RM & Weiss SR (1992) Sensitization and dopamine. *Annu Rev Psychol* 43:437–460.

87. Pringsheim T & Gardner D (2014) Natural history of EPS in antipsychotic use. *Clin Neuropharmacol* 37:84–87.

88. Reavill C et al. (2000) Adenosine A2A antagonists inhibit catalepsy. *J Pharmacol Exp Ther* 295:653–659.

89. Riederer P & Laux G (2011) Antipsychotics: from chlorpromazine to clozapine. *Handb Exp Pharmacol* 212:3–28.

90. Rowan MJ & Anwyl R (1994) NMDA receptors and synaptic plasticity. *Eur J Pharmacol* 267:11–22.

91. Sampaio C et al. (2004) Anticholinergics for drug-induced parkinsonism. *Cochrane Database Syst Rev* CD003735.

92. Sanberg PR et al. (1988) Catalepsy as a model for parkinsonism. *Pharmacol Biochem Behav* 30:199–203.

93. Saraiva C et al. (2016) Nanoparticle-mediated brain drug delivery. *Front Neurosci* 10:219.

94. Sanna E et al. (2004) GABA antagonists exacerbate EPS. *Eur J Pharmacol* 500:11–18.

95. Schotte A et al. (1996) Risperidone receptor affinity profile. *Psychopharmacology* 124:57–73.

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(5), 1235-1249 | ISSN:2251-6727

96. Seeman P & Kapur S (2000) D2 receptor occupancy and EPS. *Mol Psychiatry* 5:417–428.

97. Seeman P et al. (1993) Clozapine low EPS due to weak D2 binding. *Am J Psychiatry* 150:1443–1450.

98. Shahid M et al. (2009) Novel D2/5-HT1A partial agonist antipsychotics. *CNS Drugs* 23:225–238.

99. Sharma V et al. (2019) Advances in antipsychotic-induced catalepsy. *J Neurochem* 148:325–338.

100. Shimizu T et al. (2018) Chemogenetic control of striatal neurons in EPS. *iScience* 9:17–27.

101. Spooren WP et al. (2000) AMPA antagonists reduce catalepsy. *Neuropharmacology* 39:941–950.

102. Steullet P et al. (2014) Redox dysregulation and dopamine dysfunction. *Biol Psychiatry* 75:631–638.

103. Swanson CJ et al. (2005) NMDA antagonists and antipsychotic synergy. *J Pharmacol Exp Ther* 315:202–210.

104. Tamminga CA & Carlsson A (2002) Dopamine stabilizers in schizophrenia. *Schizophr Res* 49:21–28.

105. Tarsy D & Baldessarini RJ (2006) Drug-induced extrapyramidal syndromes. *Drug Saf* 29:425–442.

106. Tatemoto K et al. (2017) Sigma-1 agonists ameliorate catalepsy. *Neuropharmacology* 123:52–60.

107. Tembhurne SV & Sakarkar DM (2010) Ashwagandha's neuroprotective role. *J Pharmacol Pharmacother* 1:96–101.

108. Ungerstedt U (1971) 6-OHDA degeneration and supersensitivity. *Acta Physiol Scand Suppl* 367:69–93.

109. van der Schyf CJ & Geldenhuys WJ (2019) Multifunctional drugs for movement disorders. *Bioorg Med Chem Lett* 29:1033–1041.

110. Vanover KE et al. (2008) Iloperidone: receptor occupancy and EPS profile. *Eur J Pharmacol* 589:27–35.

111. Volta M & Carta-Aramburu I (2013) mGluR5 antagonists and haloperidol catalepsy. *Br J Pharmacol* 169:128–139.

112. Voronkov M et al. (2015) GSK-3 inhibitors reduce neuroleptic catalepsy. *Neuropharmacology* 89:272–280.

113. Waddington JL et al. (1995) D1–D2 receptor interactions in catalepsy. *J Psychopharmacol* 9:8–16.

114. Wang Q et al. (2021) CRISPR activation of DRD2 alleviates EPS in mice. *Mol Ther* 29:780–792.

115. Weintraub D & Comella CL (2008) Epidemiology of drug-induced parkinsonism. *Handb Clin Neurol* 83:345–350.

116. Willner P (1985) Sensitization theories of antipsychotic action. *Psychopharmacology* 87:92–99.

117. Winge K & Nielsen K (2012) Antipsychotic-induced parkinsonism in elderly. *Parkinsonism Relat Disord* 18:533–539.

118. Young AMJ (2004) Serotonin modulation of dopamine release. *J Neural Transm* 111:1575–1614.

119. Zhou FM & Palmiter RD (1995) Dopamine deficiency and motor deficits. *Cell* 83:1197–1202.

120. Zheng Y et al. (2018) CRISPR/Cas9 gene therapy for neurological disorders. *Hum Mol Genet* 27:R93–R99.